JP2006516886A5 - - Google Patents

Download PDF

Info

Publication number
JP2006516886A5
JP2006516886A5 JP2004548352A JP2004548352A JP2006516886A5 JP 2006516886 A5 JP2006516886 A5 JP 2006516886A5 JP 2004548352 A JP2004548352 A JP 2004548352A JP 2004548352 A JP2004548352 A JP 2004548352A JP 2006516886 A5 JP2006516886 A5 JP 2006516886A5
Authority
JP
Japan
Prior art keywords
composition
fusion polypeptide
amino acid
acid sequence
actriib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004548352A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006516886A (ja
JP4685452B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/031516 external-priority patent/WO2004039948A2/en
Publication of JP2006516886A publication Critical patent/JP2006516886A/ja
Publication of JP2006516886A5 publication Critical patent/JP2006516886A5/ja
Application granted granted Critical
Publication of JP4685452B2 publication Critical patent/JP4685452B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004548352A 2002-10-25 2003-10-24 Ａｃｔｒｉｉｂ融合ポリペプチドおよびその使用 Expired - Fee Related JP4685452B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42104102P 2002-10-25 2002-10-25
PCT/US2003/031516 WO2004039948A2 (en) 2002-10-25 2003-10-24 Actriib fusion polypeptides and uses therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010017449A Division JP2010138179A (ja) 2002-10-25 2010-01-28 Ａｃｔｒｉｉｂ融合ポリペプチドおよびその使用

Publications (3)

Publication Number Publication Date
JP2006516886A JP2006516886A (ja) 2006-07-13
JP2006516886A5 true JP2006516886A5 (https=) 2007-10-18
JP4685452B2 JP4685452B2 (ja) 2011-05-18

Family

ID=32230212

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004548352A Expired - Fee Related JP4685452B2 (ja) 2002-10-25 2003-10-24 Ａｃｔｒｉｉｂ融合ポリペプチドおよびその使用
JP2010017449A Withdrawn JP2010138179A (ja) 2002-10-25 2010-01-28 Ａｃｔｒｉｉｂ融合ポリペプチドおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010017449A Withdrawn JP2010138179A (ja) 2002-10-25 2010-01-28 Ａｃｔｒｉｉｂ融合ポリペプチドおよびその使用

Country Status (11)

Country Link
US (5) US20040223966A1 (https=)
EP (1) EP1572961B1 (https=)
JP (2) JP4685452B2 (https=)
AT (1) ATE448686T1 (https=)
AU (1) AU2003279817A1 (https=)
BR (1) BR0315645A (https=)
CA (1) CA2501180A1 (https=)
DE (1) DE60330181D1 (https=)
ES (1) ES2337890T3 (https=)
MX (1) MXPA05004224A (https=)
WO (1) WO2004039948A2 (https=)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200526779A (en) * 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
BR0307871A (pt) 2002-02-21 2005-04-12 Wyeth Corp Proteìnas contendo domìnio de folistatina
EP1572909A4 (en) * 2002-02-21 2007-06-06 Wyeth Corp PROTEIN CONTAINING A DOMAINE OF FOLLISTATIN
US20030219846A1 (en) * 2002-02-28 2003-11-27 Pfizer Inc. Assay for activity of the ActRIIB kinase
MXPA05002968A (es) * 2002-09-16 2005-09-08 Univ Johns Hopkins Activacion de miostatina por metaloproteasa, y metodos de modular la actividad de miostatina.
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
RU2322261C2 (ru) * 2003-06-02 2008-04-20 Уайт Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
EP3006039B1 (en) 2004-03-02 2021-01-06 Acceleron Pharma Inc. Alk7 polypeptides for use in promoting fat loss
JP2008507288A (ja) * 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
AU2015200950B2 (en) * 2004-07-23 2017-04-27 Acceleron Pharma Inc. ActRII receptor polypeptides, methods and compositions
AU2012244215B2 (en) * 2004-07-23 2014-11-27 Acceleron Pharma Inc. ActRII receptor polypeptides, methods and compositions
AU2005272646A1 (en) * 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
NZ538097A (en) * 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
EP1864138A2 (en) * 2005-03-23 2007-12-12 Wyeth Detection of gdf-8 modulating agents
JP2008537777A (ja) * 2005-03-23 2008-09-25 ワイス Ｇｄｆ−８調節剤に対する免疫応答の検出
PL2407486T3 (pl) 2005-08-19 2018-05-30 Wyeth Llc Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8
US8067562B2 (en) * 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
AU2011237541B2 (en) * 2005-11-01 2014-05-15 Amgen Inc. Novel activin receptor and uses thereof
ES2649983T3 (es) * 2005-11-23 2018-01-16 Acceleron Pharma, Inc. Antagonistas de activina-ActRIIa en su uso para promover el crecimiento óseo
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
AU2013221910B2 (en) * 2006-12-18 2016-11-17 Acceleron Pharma Inc. Activin-ActRII antagonists and uses for increasing red blood cell levels
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
US8895016B2 (en) * 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
AU2016250354B2 (en) * 2006-12-18 2019-01-17 Acceleron Pharma Inc. Activin-ActRII antagonists and uses for increasing red blood cell levels
CN104524548A (zh) * 2006-12-18 2015-04-22 阿塞勒隆制药公司 活化素-actrii拮抗剂及在提高红细胞水平中的用途
MX2009008222A (es) * 2007-02-01 2009-10-12 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TW201803890A (zh) * 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
AU2013203266B2 (en) * 2007-02-02 2016-04-28 Acceleron Pharma Inc. Variants derived from ActRIIB and uses therefor
EA018221B1 (ru) 2007-02-09 2013-06-28 Акселерон Фарма Инк. АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
CA2685540C (en) 2007-08-03 2018-10-16 Graham Michael Wynne Drug combinations for the treatment of duchenne muscular dystrophy
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
CN102131822A (zh) * 2008-06-26 2011-07-20 阿塞勒隆制药公司 进行激活素-ActRIIa拮抗剂给药和监测受治疗患者的方法
DK2318028T3 (da) * 2008-06-26 2020-05-04 Acceleron Pharma Inc Antagonister af opløselig activin-aktriia og anvendelser til øgning af røde blodcelleniveauer
US20100061976A1 (en) * 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
TW201803586A (zh) 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
JP5611222B2 (ja) 2008-11-26 2014-10-22 アムジエン・インコーポレーテツド アクチビンｉｉｂ受容体ポリペプチドの変異体及びその使用
AU2010204985A1 (en) 2009-01-13 2011-08-04 Acceleron Pharma Inc. Methods for increasing adiponectin
KR20120049214A (ko) * 2009-06-08 2012-05-16 악셀레론 파마 인코포레이티드 발열성 지방세포를 증가시키는 방법
KR20180026795A (ko) 2009-06-12 2018-03-13 악셀레론 파마 인코포레이티드 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
EP3202459B1 (en) * 2009-09-09 2021-04-14 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content
AU2010315245B2 (en) 2009-11-03 2016-11-03 Acceleron Pharma Inc. Methods for treating fatty liver disease
EP3332796A1 (en) 2009-11-17 2018-06-13 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US20110268736A1 (en) * 2010-04-30 2011-11-03 Children's Medical Center Corporation Method for treating congenital myopathy
JP2013535981A (ja) 2010-08-20 2013-09-19 ワイス・エルエルシー 成長因子不含適合細胞の細胞培養
AU2011326586A1 (en) 2010-11-08 2013-05-30 Acceleron Pharma, Inc. ActRIIA binding agents and uses thereof
SG194787A1 (en) * 2011-05-06 2013-12-30 Us Gov Health & Human Serv Recombinant immunotoxin targeting mesothelin
RU2663794C2 (ru) 2011-10-21 2018-08-09 Пфайзер Инк. Добавление железа для улучшения культивирования клеток
HK1203384A1 (en) * 2011-12-19 2015-12-11 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
KR101704893B1 (ko) 2012-06-15 2017-02-08 화이자 인코포레이티드 Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도
US9873739B2 (en) 2012-08-01 2018-01-23 Ikaika Therapeutics, Llc Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (LTBP4)
WO2014030683A1 (ja) * 2012-08-21 2014-02-27 国立大学法人九州大学 貧血患者の貧血の要因を検出するためのバイオマーカー
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
AU2014212014A1 (en) 2013-02-01 2015-08-27 Amgen Inc. Administration of an anti-activin-A compound to a subject
RS61778B1 (sr) 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
US10358476B2 (en) 2015-04-06 2019-07-23 Acceleron Pharma Inc. Single arm type I and type II receptor fusion proteins and uses thereof
MA41920B1 (fr) 2015-04-06 2021-05-31 Acceleron Pharma Inc Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
CA2983440C (en) 2015-04-22 2024-03-12 Alivegen Usa Inc. Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
MA45811A (fr) 2016-07-27 2019-06-05 Acceleron Pharma Inc Méthodes et compositions de traitement de maladie.
CA3039573A1 (en) 2016-10-05 2018-04-12 Acceleron Pharma Inc. Alk4:actriib heteromultimers and uses thereof
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
NZ754161A (en) 2016-11-10 2025-11-28 Keros Therapeutics Inc Activin receptor type iia variants and methods of use thereof
GB201620119D0 (en) * 2016-11-29 2017-01-11 Pharmafox Therapeutics Ag Compounds
CA3082146A1 (en) 2017-11-09 2019-05-16 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
IL320014A (en) 2018-01-12 2025-06-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of use thereof
KR20250133994A (ko) 2018-05-09 2025-09-09 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
WO2020132647A1 (en) 2018-12-21 2020-06-25 Northwestern University Use of annexins in preventing and treating muscle membrane injury
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
WO2021189019A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Activin receptor type ii chimeras and methods of use thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
JP2807287B2 (ja) * 1989-10-13 1998-10-08 株式会社医学生物学研究所 ペプチドおよびその用途
US6162896A (en) * 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5573924A (en) * 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
US6673534B1 (en) * 1995-10-26 2004-01-06 The Johns Hopkins University School Of Medicine Methods for detection of mutations in myostatin variants
DK0690873T3 (da) * 1993-03-19 2003-09-29 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-8
US6607884B1 (en) * 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US20030074680A1 (en) * 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US5994618A (en) * 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US6465239B1 (en) * 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
WO1994026892A1 (en) * 1993-05-12 1994-11-24 Genetics Institute, Inc. Bmp-11 compositions
US5831050A (en) * 1993-06-07 1998-11-03 Creative Biomolecules, Inc. Morphogen cell surface receptor
EP1716864A1 (en) * 1993-08-26 2006-11-02 Genetics Institute, LLC Neural regeneration using home bone morphogenetic proteins
US7332575B2 (en) * 1994-03-18 2008-02-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
EP1574577A3 (en) * 1994-07-08 2006-06-14 The Johns Hopkins University School Of Medicine Growth differentiation factor-11
US5545616A (en) * 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6121415A (en) * 1997-07-09 2000-09-19 Genentech, Inc. ErbB4 receptor-specific neuregolin related ligands and uses therefor
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6369201B1 (en) * 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
US6004937A (en) * 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
JP4544742B2 (ja) * 1998-05-06 2010-09-15 メタモーフイクス・インコーポレーテツド Ｇｄｆ−８の阻害による糖尿病の処置法
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US7037501B2 (en) * 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
TW200526779A (en) * 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
EP1572909A4 (en) * 2002-02-21 2007-06-06 Wyeth Corp PROTEIN CONTAINING A DOMAINE OF FOLLISTATIN
BR0307871A (pt) * 2002-02-21 2005-04-12 Wyeth Corp Proteìnas contendo domìnio de folistatina
MXPA05002968A (es) * 2002-09-16 2005-09-08 Univ Johns Hopkins Activacion de miostatina por metaloproteasa, y metodos de modular la actividad de miostatina.
AR047392A1 (es) * 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
BR0317538A (pt) * 2002-12-20 2005-11-29 Amgen Inc Agente ligante, sequência de polinucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos de inibir a atividade de miostatina, de aumentar a massa muscular magra e a razão de massa muscular magra para gordura, de tratar uma doença de emaciação muscular e um distúrbio metabólico relacionado com miostatina em um indivìduo, de detectar e medir miostatina em uma amostra, e, de diagnosticar um distúrbio relacionado com miostatina em um indivìduo
WO2005028517A2 (en) * 2003-05-09 2005-03-31 The General Hospital Corporation SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS
RU2322261C2 (ru) * 2003-06-02 2008-04-20 Уайт Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
US20050157125A1 (en) * 2004-01-21 2005-07-21 Silverbrook Research Pty Ltd Inkjet printer cartridge with integral shield
EP1864138A2 (en) * 2005-03-23 2007-12-12 Wyeth Detection of gdf-8 modulating agents
JP2008537777A (ja) * 2005-03-23 2008-09-25 ワイス Ｇｄｆ−８調節剤に対する免疫応答の検出

Similar Documents

Publication Publication Date Title
JP2006516886A5 (https=)
US11932677B2 (en) Hybrid ActRIIB ligand trap proteins for treating muscle wasting diseases
Winkler et al. The crystal structure of EcoRV endonuclease and of its complexes with cognate and non‐cognate DNA fragments.
Miura et al. Molecular cloning of nucleobindin, a novel DNA-binding protein that contains both a signal peptide and a leucine zipper structure
US12187783B2 (en) Methods for treating muscle wasting and bone disease using novel hybrid ActRIIB ligand trap proteins
Yoshida et al. Dissociation of the complex of dystrophin and its associated proteins into several unique groups by n‐octyl β‐D‐glucoside
JP2008507292A (ja) リンカー
EP0375736B1 (en) Nucleic acid fragments encoding mannose binding fragments of human mannose binding protein
Wang et al. The specific binding of Escherichia coli integration host factor involves both major and minor grooves of DNA
RU2005115477A (ru) Нейтрализующие антитела против gdf-8 и их применение
Laitinen et al. Chicken avidin-related proteins show altered biotin-binding and physico-chemical properties as compared with avidin
JP2001511347A5 (https=)
HUT70459A (en) Analogs of pth
WO2009123950A2 (en) Chimera comprising bacterial cytotoxin and methods of using the same
JP2013520487A5 (https=)
WO2004035753B1 (en) Lmna gene and its involvement in hutchinson-gilford progeria syndrome (hgps) and arteriosclerosis
WO2002092829A1 (en) Process for producing peptide
JPH05271279A (ja) ヒト副甲状腺ホルモンムテインおよびその製造法
Carpenter et al. The cDNA sequence of horse transferrin
US20070054364A1 (en) Polypeptide variants
JP2729712B2 (ja) 機能性ポリペプチド
JP2002508181A5 (https=)
JP2008514227A5 (https=)
JP2023549323A5 (https=)
JP2024538595A5 (https=)